Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880752 | 1.00 | GID4 (0.35) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL30113715 | 1.00 | GID4 (0.35) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL1873780 | 1.00 | GID4 (0.35) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL9277476 | 0.84 | FFAR1 (0.38) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL9277471 | 0.84 | FFAR1 (0.38) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL8846318 | 0.83 | ADRA2A (0.30) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL9278190 | 0.83 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL9277540 | 0.83 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL29944717 | 0.81 | — | — | |
| SCHEMBL9280511 | 0.81 | DRD2 (0.37) | DRD2DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110300755-B | Indanyl amino aza dihydro benzofuran acetic acid, pharmaceutical composition for treating diabetes | 勃林格殷格翰国际有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-3580222-B1 | INDANYLAMINOAZADIHYDROBENZOFURANYLACETIC ACIDS, PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-10550127-B1 | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-04 | — | — | US | disclosed |
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018146008-A1 | INDANYLAMINOAZADIHYDROBENZOFURANYLACETIC ACIDS, PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-16 | — | — | WO | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2012158550-A9 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2012158550-A9 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9481659-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2016-11-01 | — | — | US | disclosed |
| US-9481659-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2016-11-01 | — | — | US | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-8507538-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | RECEPTOS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507538-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | RECEPTOS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012158550-A2 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2011-07-28 | — | — | US | disclosed |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, INSR, GPR52 | GID4 221/4885DRD2 638/4885DRD1 883/4885 |
| US-10550127-B1 | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes | GPR119, GPR55, GPR65 | GID4 90/4885DRD2 991/4885DRD1 1406/4885 |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | GID4 1514/4885DRD2 1847/4885DRD1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.